PF-Atlas › Treatments › GLP-1 Agonist Anti-Fibrotic Repurposing
GLP-1 Agonist Anti-Fibrotic Repurposing
GLP-1 receptor agonists (semaglutide/liraglutide) show anti-fibrotic + anti-inflammatory effects across organs
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase I/II (repurposing)
Evidence level
Level 2 (Repositioning)
Mechanism class
GLP-1 receptor agonists (semaglutide/liraglutide) show anti-fibrotic + anti-inflammatory effects across organs
Timeline
1-3 years
Risk profile
Low
Developer
Novo Nordisk / Eli Lilly
Key researchers
Multiple
Overview
Liraglutide decreased collagen expression in experimental lung fibrosis, restored ACE2 levels, increased surfactant production. Semaglutide FDA-approved Jan 2025 for kidney fibrosis protection. Anti-inflammatory meta-analysis confirms CRP/IL-6 reduction. GLP-1 receptors present on alveolar epithelium. Fastest repurposing path — already FDA-approved, safety profile established.
How GLP-1 Agonist Anti-Fibrotic Repurposing fits into IPF treatment
GLP-1 Agonist Anti-Fibrotic Repurposing is classified as Level 2 (Repositioning) at the Phase I/II (repurposing) stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about GLP-1 Agonist Anti-Fibrotic Repurposing for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.